WO2018112475A1 - Compositions énergisantes et procédés - Google Patents

Compositions énergisantes et procédés Download PDF

Info

Publication number
WO2018112475A1
WO2018112475A1 PCT/US2017/067116 US2017067116W WO2018112475A1 WO 2018112475 A1 WO2018112475 A1 WO 2018112475A1 US 2017067116 W US2017067116 W US 2017067116W WO 2018112475 A1 WO2018112475 A1 WO 2018112475A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
oral composition
theacrine
cannabis
effect
Prior art date
Application number
PCT/US2017/067116
Other languages
English (en)
Inventor
Scott Martin
Original Assignee
Hempep, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hempep, Inc. filed Critical Hempep, Inc.
Publication of WO2018112475A1 publication Critical patent/WO2018112475A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins

Definitions

  • the field of the invention is dietary supplements, especially dietary supplements providing an energy enhancing effect.
  • Yerba mate is a plant stimulant that is relatively high in caffeine content and has gained popularity in recent years as an energy enhancing stimulant. Yerba mate is believed to offer a wide variety of benefits, for example, relief of mental and physical fatigue, improvement in mood and depression, appetite suppression and fat burning capabilities.
  • yerba mate is thought to be safe when consumed in low or moderate amounts, similar to other caffeine-containing foods or drinks, its consumption in larger doses often causes several undesired symptoms such as jitters, anxiety, cardiac effects (e.g., increased heart rate, increased blood pressure), nervousness, restlessness, osteoporosis, irritable bowel syndrome and even certain forms of cancers.
  • These negative effects associated with yerba mate can be exacerbated when consumed as a tea or in combination with certain medications, cigarettes or alcohol.
  • yerba mate In other known energy formulations, selected cannabinoids were combined with a caffeinated ingredient such as yerba mate.
  • Cannabinoids have been generally known as having a calming effect, including sleep induction sleep, preventing nausea, and relieving pain, as opposite to caffeine.
  • U.S. Pat. Pub. No. 2016/0324776 to Glatzel teaches that a combination of yerba mate and cannabinoids would provide both alertness and a calming effect.
  • U.S. Pat. Pub. No. 2016/0324776 to Victor discloses a yerba mate drink containing cannabinoid compounds.
  • both Glatzel and Victor do not provide any concentrations of yerba mate and cannabinoid to provide both alertness and calming effect at a desired level, and even fail to indicate whether a combination of yerba mate and cannabinoids would be even sufficient to provide both alertness and calming effect at any desired level.
  • the inventive subject matter is directed to various compositions of, methods for, and uses of a combination of a plant stimulant, a theacrine containing component, and a cannabis component to provide a consumer sufficient energy-enhancing effect while reducing undesired effects of stimulants.
  • compositions including a combination of yerba mate extract and theacrine can include a lower dose of yerba mate when compared to known oral yerba mate formulations, while providing substantially the same or even greater energy boosting effects. Therefore, energy boosting effects of yerba mate components can be obtained even at large doses without the negative effects associated with larger doses of yerba mate.
  • the inventors unexpectedly discovered that combining a cannabis component, and particularly cannabidiol (and/or other non-psychotropic cannabinoids) with yerba mate in combination with a theacrine containing component substantially maintains the substantially enhanced stimulant effect while reducing undesirable side effects of the stimulating component(s).
  • one aspect of the subject matter includes an oral composition including a plant stimulant component, a theacrine containing component, and a cannabis component.
  • the theacrine containing component is present in an amount sufficient to enhance a first effect of the plant stimulant component and the cannabis component is present in an amount effective to reduce a second effect of the plant stimulant component.
  • the plant stimulant component is obtained from a yerba mate leaf extract
  • the theacrine containing component can be obtained from Camellia Kucha tea leaves.
  • the oral composition can further include a ginger component, a turmeric component, and a vitamin B component.
  • the inventors contemplate an oral composition that includes a yerba mate component, a Camellia Kucha component, and a cannabidiol fraction.
  • the Camellia Kucha containing component is present in an amount sufficient to enhance a first effect of the yerba mate component and the cannabidiol fraction is present in an amount effective to reduce a second effect of the yerba mate component.
  • the composition may further include at least one of, or a plurality of a green tea component, a ginger root component, a curcumin component, and a vitamin B component.
  • the inventors contemplate an oral composition that comprises a stimulant composition that essentially consists of a plant stimulant component, a theacrine containing component, and a cannabis component.
  • the theacrine containing component is present in an amount sufficient to enhance a first effect of the plant stimulant component and the cannabis component is present in an amount effective to reduce a second effect of the plant stimulant component.
  • the inventors contemplate use of above oral compositions for treating or reducing stimulant addiction.
  • Still another aspect of the inventive subject matter includes a method of modifying activity of a yerba mate component containing mixture for an oral composition.
  • a theacrine containing component is added to the mixture in an amount effective to enhance an energy improving effect of the yerba mate plant component.
  • the mixture for the oral composition includes a cannabis component to reduce a negative effect of the yerba mate plant component.
  • the oral composition can further include a ginger component, a turmeric component, and a vitamin B component.
  • Still another aspect of the inventive subject matter includes a method of modifying an activity of a mixture for an oral composition.
  • the mixture for an oral composition includes a yerba mate component and a theacrine containing component, and theacrine containing component is present in an amount sufficient to enhance an energy improving effect of the yerba mate component .
  • a cannabis component to the mixture in an amount effective to reduce a negative effect of a combination of the theacrine containing component and the yerba mate component present in the mixture
  • an oral composition comprising a plant stimulant component, a theacrine containing component, and a cannabis component is formulated or provided.
  • the term "provide” or “providing” refers to and includes any acts of manufacturing, generating, placing, enabling to use, or making ready to use.
  • the theacrine containing component is present in an amount effective to modify an energy increasing capability of the plant stimulant component
  • the cannabis component is present in an amount effective to reduce a negative side effect of at least one of the plant stimulant component and the theacrine containing component.
  • a dose of the oral composition effective to enhance the energy level of the person can be administered to the person to enhance the energy level of the person, while, preferably, reducing a negative side effect of at least one of the plant stimulant component and the theacrine containing component.
  • a theacrine component and a cannabis component can be combined with a plant stimulant component, such that the theacrine component is effective to enhance and/or prolong a desired effect of the plant stimulant component (e.g., energy boost, appetite suppression, improved mood, etc.), and the cannabis component is effective to reduce a negative effect of the plant stimulant component (e.g., jitters, nervousness, anxiousness, fear, etc.) without substantially affecting the desired effect.
  • a desired effect of the plant stimulant component e.g., energy boost, appetite suppression, improved mood, etc.
  • the cannabis component is effective to reduce a negative effect of the plant stimulant component (e.g., jitters, nervousness, anxiousness, fear, etc.) without substantially affecting the desired effect.
  • the plant stimulant component includes a yerba mate (also known as Ilex paraguariensis) leaf extract.
  • a yerba mate also known as Ilex paraguariensis
  • Any suitable methods of producing the yerba mate extract are contemplated.
  • the yerba mate extract can be generated from fresh leaves of yerba mate plant or a dried (at least 30% dried, at least 50% dried, at least 90% dried, at least 99% dried) leaves of yerba mate plant.
  • the yerba mate extract can be a crude extract (aqueous, alcoholic, or non-aqueous) that contains a mixture of xanthines (e.g., caffeine), flavonoids (e.g., quercetin), saponins (e.g., ursolic acid), and/or cinnamic acid (e.g., chlorogenic acid) compounds at a natural concentration or at ratios that are naturally present in the yerba mate plant leaves.
  • xanthines e.g., caffeine
  • flavonoids e.g., quercetin
  • saponins e.g., ursolic acid
  • cinnamic acid e.g., chlorogenic acid
  • the yerba mate extract can be an extract with a boosted amount of xanthines (e.g., caffeine), flavonoids (e.g., quercetin), saponins (e.g., ursolic acid), and/or cinnamic acid (e.g., chlorogenic acid) compounds by, for example, artificially adding one or more of those compounds or extracted using a protocol to remove or concentrate one or more of those compounds.
  • the extracts will be standardized to a specific caffeine concentration (e.g., to contain 5 wt%, 10 wt%,15 wt%, or 20 wt%, caffeine).
  • theacrine containing component can additionally potentiate the duration of an effect of the plant stimulant component.
  • theacrine acts as a synergistic component for the stimulant effect of the plant stimulant, and particularly for the yerba mate extract.
  • the theacrine component can be any components including, or derivative component including 1,3,7,9-tetramethyluric acid (a caffeine derivative) or the derivative thereof, in a liquid or a solid form.
  • the theacrine component can be obtained or derived from Chinese tea known as kudingcha (Camellia assamica var. kuch , or Camellia Kucha), or its extract.
  • the theacrine component can be an extract (aqueous or non-aqueous) of Camellia Kucha, generated from fresh leaves of Camellia Kucha or a dried (at least 30% dried, at least 50% dried, at least 90% dried, at least 99% dried) leaves of Camellia Kucha.
  • the theacrine component can be a purified chemical or a chemical mixture that has 1,3,7,9-tetramethyluric acid at a concentration of higher than 10%, higher than 20%, higher than 30%, higher than 50% , or higher than 70%, etc.
  • the theacrine component may be TEACRIN® (theacrine supplement available from Double Wood Supplements, 3510 Scotts Lane, Philadelphia, PA 19128)
  • theacrine component and the yerba mate component are present in the composition in synergistic amounts (e.g., ratio, weight/volume, etc.) with respect to at least one desired effect, including, but not limited to enhanced energy levels, appetite suppression, fat burning capabilities, improved mood or motivation, or heightened mental focus.
  • the beneficial effects of yerba mate components can typically last for about 1 hours when consumed without a theacrine containing component, formulations including both yerba mate and theacrine components can prolong the beneficial effects for at least 2 hours, at least 4 hours, at least 5 hours or even 6 or more hours.
  • theacrine component and the yerba mate component are present in the composition in an amount or ratio that does not significantly change (or negatively affect) any vital signs (e.g., blood pressure, respiratory rate, pulse rate, body temperature, etc.) quantitatively or qualitatively. .
  • the inventors contemplate that increases in beneficial effects of yerba mate component such as enhanced energy levels are typically accompanied by increases in adverse effects, especially jitteriness, anxiety, and nervousness.
  • the inventors further contemplate that by adding the theacrine components in the composition, the amount of the yerba mate component in the composition can be decreased as 1 ,3,7,9-tetramethyluric acid of the theacrine components can provide a similar effect with the caffeine of the yerba mate component.
  • the beneficial effect of the composition can be prolonged, but the negative or undesired effect of the composition can be decreased as the relative concentration of the yerba mate component can be decreased with increased theacrine component concentration.
  • the cannabis component can soften the effects of coming down after the energy boost provided by the yerba mate and theacrine components, making the come down much more subtle, gradual and tolerable.
  • the cannabis component can comprise at least one of a cannabidiol, a tetrahydrocannabinol, a cannabinol, a cannabichromene, and a cannabigerol.
  • a cannabidiol hemp oil concentrate e.g., HempCHOICE® produced by Source 1 Global Partners
  • HempCHOICE® produced by Source 1 Global Partners
  • the hemp oil concentrate has a high CBD (cannabidiol) content and a low THC (tetrahydrocannabinol) content.
  • the cannabis component comprises a cannabidiol with less than 3 wt% of THC, and typically less than 1 wt% of THC, even more typically less than 0.5 wt% of THC, and most typically less than 0.25 wt% of THC (e.g., formulated with C02 extraction).
  • the high-CBD content is at least 10 wt%, more typically at least 15 wt%, even more at least 20 wt%, and most typically at least 25 wt%.
  • the high CBD/low THC cannabis component can be obtained from a high CBD/low THC cannabis strains, or can be obtained by processes that remove THC content or convert THCs into CBDs.
  • cannabinoid component with energy boosting component (e.g., theacrine component or yerba mate component, or both)
  • energy boosting component e.g., theacrine component or yerba mate component, or both
  • a composition can be formulated such that the effect of an energy boosting component can be maintained (or even boosted further) while the undesired side effect can be substantially reduced as two or more components having opposite effects can often compromise their effects rather than selectively strengthen or weakening the desired or undesired effects, respectively.
  • the yerba mate or other plant stimulant component and the cannabis component can be present in any suitable weight ratio or molar ratio to reduce the negative effects of the plant stimulant component.
  • it may vary depending on the types of plant stimulant component and the cannabis component and the initial concentration of xanthines (e.g., caffeine) and CBD in those components, respectively.
  • the ratio between the yerba mate leaf extract and the hemp oil concentrate can be between 4: 1 and 12: 1, preferably between 6: 1 and 10: 1, more preferably between 7: 1 and 9: 1 , and most preferably around or about 8: 1.
  • the weight ratio of the plant stimulant component can be lower than the cannabis component if the cannabis component has lower concentration of CBD and the plant stimulant component has higher concentration of caffeine or chemicals with similar characteristics.
  • the ratio between the plant stimulant component and the cannabis component can be between 1 :4 and 1 : 12, between 1 :6 and 1 : 10, and between 1 :7 and 1 :9.
  • the yerba mate component is mixed with the theacrine containing component to produce synergistic effect of boosting the energy in a consumer, and further mixed with the cannabis component to reduce the negative effects of at least one of the plant stimulant component and the theacrine component.
  • the theacrine containing component and the cannabis component can also be present in any suitable weight ratio or molar ratio to achieve such effects.
  • the ratio may vary depending on the types of theacrine component and the cannabis component and the initial concentration of theacrine and CBD in those components, respectively.
  • the weight ratio between the yerba mate leaf extract and the theacrine component can be between 4: 1 and 12: 1, preferably between 6: 1 and 10: 1, more preferably between 7: 1 and 9: 1, and most preferably around or about 8: 1.
  • the weight ratio between the theacrine component and the cannabis component can be between 0.1 :5 and 5:0.1, preferably between 0.
  • the energy boosting energy compositions of the inventive subject matter can comprise additional active and inactive ingredients, including for example, a ginger component, a turmeric component, a vitamin B component, a green tea component, or any other suitable components.
  • the energy boosting effects can be provided solely by the specific and sometimes synergistic combinations of the plant stimulant component and the theacrine component in the noted quantities or relative proportions, and that the reduction in jitters caused by the plant stimulant component can be provided solely by the addition of the cannabis component.
  • the turmeric component can comprise at least one of turmeric, a turmeric extract, a curcumin, a desmethoxycurcumin, a bis-desmethoxy curcumin, a rosocyanine, and a curcumin
  • the turmeric component comprises a curcumin phosphatidylcholine complex (e.g., Meriva®). It is contemplated the turmeric component can comprise (i) an individual turmeric component (e.g., curcumin phosphatidylcholine complex), or (ii) a combination of at least two of a turmeric, a turmeric extract, a curcumin, a
  • the ginger component comprises at least one of a ginger, a ginger root extract, a shogaol, a zingerone, and a gingerol and provide a beneficial effect (e.g., an anti-inflammatory effect).
  • the ginger component comprises a ginger root extract (standardized to 5% gingerol).
  • the ginger component can comprise (i) an individual ginger component (e.g., the ginger root extract), or (ii) a combination of at least two of a ginger, a ginger root extract, a shogaol, a zingerone, and a gingerol.
  • green tea leaf extracts containing green tea catechins are preferred, and can provide an antioxidative effect.
  • the green tea leaf extract can comprise a strong infusion, a soft extract, a dry extract, a partly purified extract or any combination thereof.
  • the green tea catechins found in green tea extracts namely epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG) and epigallocatechin gallate (EGCG)
  • EC epicatechin
  • ECG epicatechin gallate
  • EGCG epigallocatechin gallate
  • two or more of the turmeric, ginger and green tea components are provided in a synergy blend that results in an anti-inflammatory, antioxidative or any other effects that can be quantitatively and qualitatively greater than the sum of the individuals.
  • the synergy blend (or its components) can make additional energy available to the person that would otherwise be needed to fight inflammation.
  • the synergy blend can comprise any suitable wt% of the formulation's active or inactive ingredients, including for example, between l-25wt%, between 5-15wt%, and more preferably between 7-10wt%.
  • a vitamin B component can be added to the composition to provide synergistic effect in boosting energy without adding any significant side effect.
  • the vitamin B component can comprise at least one of methylcobalamin, cyanocobalamin, hydroxocobalamin, adenosylcobalamin, a vitamin B6, and biotin.
  • the vitamin B component comprises a vitamin B12 from methylcobalamin.
  • each of the plant stimulant component, theacrine containing component, the cannabis component, the turmeric component, the ginger component, the vitamin B component (e.g., vitamin B12, etc.) and the green tea component can comprise one or more ingredients (e.g., the ginger component include both ginger root extract and shogaol, etc.). Additionally or alternatively, each of the components can be present in the energy boosting formulation in any suitable ratio relative to one, some or all of the components. Additionally or alternatively, each of the vitamin B, ginger, green tea and turmeric components can be present in the formulation in any suitable ratio relative to the plant stimulant component, including for example.
  • each of the vitamin B, ginger, green tea and turmeric components can be present in any suitable ratio relative to the theacrine containing component. Additionally or alternatively, each of the vitamin B, ginger, green tea and turmeric components can be present in any suitable ratio relative to the cannabis component.
  • the additional active or inactive ingredients i.e., other than yerba mate leaf extract, Teacrine® and HempCHOICE®
  • the yerba mate leaf extract, Teacrine® and HempCHOICE can comprise at least 60wt%, at least 70wt%, at least 80wt%, or even 90wt% or more of the total weight of the formulation.
  • components of the inventive composition are preferably provided in a single composition comprising each of at least the plant stimulant, theacrine and cannabis components, it is also contemplated that the components can be administered sequentially individually or in groups.
  • the energy and mood enhancing effects with reduced jitters can be provided using only the plant stimulant, theacrine and cannabis components, some contemplated compositions can have a set of active ingredients consisting of or essentially consisting of the plant stimulant, theacrine and cannabis components.
  • compositions can have a set of active ingredients consisting of or essentially consisting of the plant stimulant, theacrine, cannabis, ginger, turmeric and green tea components.
  • the quantities of each component can be modified to customize the energy boosting compositions to provide the level of a beneficial effect desired by the consumer.
  • quantities of the plant stimulant or the theacrine containing component may be disproportionately increased relative to the examples provided for the other components for a user having a high caffeine/stimulant tolerance.
  • a quantity of the cannabis component may be disproportionately increased relative to the examples provided for the other components for a user having abnormally high anxiety levels. Therefore, it should be recognized that the amount of active ingredients in contemplated compositions can vary significantly. However, it is generally preferred that the active ingredients are present in a minimum amount effective to deliver the desired beneficial effects.
  • Contemplated compositions can be formulated to comprise any suitable amount of each of the various components, for example, in a single dose.
  • contemplated compositions can be formulated comprise between 100-600mg, between 200-450mg, or between 150-425mg of a yerba mate component per dosage unit. Additionally or
  • contemplated compositions can comprise between 5-200mg, between 5-100mg, or between 25-75mg of the theacrine containing component per dosage unit. Additionally or altematively, contemplated compositions can comprise between 5-200mg, between 5-100mg, or between 25-75mg of the cannabis component per dosage unit. Additionally or alternatively, contemplated compositions can comprise between 0-l,000mcg, between 100- 800mcg, or between 300-600mcg of the vitamin B component per dosage unit. Additionally or alternatively, contemplated compositions can comprise between 0-200mg, between 5- lOOmg, or between 25-75mg of the synergy blend per dosage unit. Additionally or alternatively, contemplated compositions can comprise between 0-lOOmg, between 5-75mg, or between 25-60mg of the green tea component per dosage unit. Additionally or
  • contemplated compositions can comprise between 0-lOOmg, between 5-75mg, or between 25-60mg of the ginger component per dosage unit. Additionally or alternatively, contemplated compositions can comprise between 0-lOOmg, between 5-75mg, or between 25-60mg of the turmeric component per dosage unit. All combinations of all of the ranges provided herein are also contemplated.
  • contemplated compositions for energy boosting formulations include an amount of some or all of the components that is less than the amount found in known single active component supplements.
  • known single active component yerba mate supplements include 600 mg of yerba mate leaf extract and is suggested to be taken up to four times per day.
  • preferred compositions comprise a dose of the yerba mate component (e.g., yerba mate leaf extract, typically as concentrate between 1-20 %, preferably between 5-10 %, such as 8%) of about 400 ⁇ 50 mg suggested to be taken once or twice daily.
  • a dose of 400 ⁇ 50 mg of yerba mate present in a mixture with a dose of 50 ⁇ 20 mg of the theacrine component (and optionally 50 ⁇ 20 mg of the cannabis component) is effective to have the energy boosting effect of between 600-1800mg of yerba mate present in an oral formulation without the theacrine component.
  • Such low doses of yerba mate-based ingredients are expected to increase tolerability and reduce the risk of adverse side effects associated with known yerba mate supplements.
  • the contemplated compositions can be formulated in any suitable carriers or forms for oral administration to the consumers. Especially preferred compositions are formulated in hard or soft gelcaps or tablets for oral administration. Additionally, the energy boosting compositions can be incorporated into medical foods. While yerba mate doses for capsules and tablets can typically be between about 200-450mg, it is contemplated that the doses for medical food preparations may be significantly higher and include 600-2,500mg, 2,000- 4,000mg, 3,000-7,000mg, 7,000-10,000mg, and even higher. Customized doses of the energy boosting compositions can be formulated and provided to meet an individual's specific needs. Contemplated doses include both low (e.g., about 100-200mg, about 200- 300mg) and higher doses.
  • compositions can be formulated as an energy drink.
  • such energy drink includes sugar or other carbohydrates in less than 20%, preferably less than 10%, more preferably less than 5% weight/volume of the drink, and/or less than 20%, preferably less than 10%, more preferably less than 5% of the daily dietary recommended or maximum amount (e.g., 37.5 g for men, and 25 g for women, etc.). It is also contemplated that some flavor can be added to make the energy drink more palatable, for example, by adding coconut juice, coconut concentrate, fruit flavors, coffee flavors, and so on. Alternatively, the liquid base may also be a fruit juice, coconut water, coffee, or tea. Most typically, the overall dosages of contemplated ingredients will be the same as indicated above, and may be present in or delivered to the energy drink as a mix-in (e.g., from a separate compartment where stability or appearance issues are encountered).
  • a mix-in e.g., from a separate compartment where stability or appearance issues are encountered.
  • the administration of the suitable dose can be administered once per day, or can be spread out over the course of a day.
  • an effective dose of the composition can be divided and separately packaged as two to five capsules, tablets, powders, oral dissolve strips, syrups, suspensions, wafers, and separately administered two to five times a day.
  • the pharmaceutical preparations can be made following the conventional techniques of pharmacy involving milling, mixing, granulation, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • the dosage unit form is a capsule, it may additionally contain a pharmaceutically acceptable carrier, such as a liquid carrier (e.g., a fatty oil).
  • a pharmaceutically acceptable carrier such as a liquid carrier (e.g., a fatty oil).
  • Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, such as, for example, a coating.
  • tablets or pills may be coated with sugar, shellac, or other enteric coating agents.
  • Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
  • “Pharmaceutically acceptable carrier” refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body.
  • the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof.
  • Each component of the carrier must be “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the formulation.
  • compositions according to the inventive subject matter may be administered using various routes.
  • contemplated compositions can be administered topically via a transdermal patch, cream or ointment, possibly with penetration enhancers and administered to skin over the carotid artery.
  • compositions described above modify an activity of a plant stimulant component, especially yerba mate component independently.
  • the amount of theacrine containing component mixed with the yerba mate component is contemplated to enhance an energy improving (or other beneficial) effect of the yerba mate plant component or provide synergistic effect (i.e., increase of the energy improvement effect more than the sum of individual effect of each component, at least 5%, at least 10%, at least 20% more, etc.).
  • a negative effect of yerba mate component or theacrine component, or both can be minimized or reduced by adding a cannabis component in an effective amount. It should be appreciated that such increasing positive effect and decreasing negative effect without compromising each other such that the positive effect is increased with addition of theacrine component, and not significantly decreased by addition of cannabinoid component.
  • the level of the positive effect and the level of the undesired or negative effect can be measured or at least estimated using various methods, including, but not limited to a visual analog scale, questionnaires, and observations.
  • Table 2 provides one exemplary test results of an individual measuring the positive effect and the negative effect by questionnaires. The individual was provided with 1) yerba mate component only, 2) yerba mate component + theacrine component, 3) yerba mate component + cannabinoid component, 4) yerba mate component + theacrine component + cannabinoid component, and 5) a control, placebo component (nonactive substances only).
  • theacrine component could increase the alertness level of the individual independently to the addition of cannabinoid component, and the cannabinoid component could increase the calming effect (less jitteriness) significantly without reducing the positive effect of theacrine component and yerba mate component.
  • compositions described above with increased positive effect (e.g., alertness) and decreased negative or undesired effect (e.g., jitteriness), can be used to treat a stimulant-addicted person or reducing the stimulant-addiction in a person.
  • a dose of the compositions can be provided or administered to a stimulant-addicted person to consume instead of the stimulants (prescribed or non-prescribed), in a schedule effective to reduce the addiction to the stimulant substance (e.g., less craving for the stimulant substances, maintaining emotional and mental stability without the stimulant substance, etc.).
  • administering refers to both direct and indirect administration, wherein direct administration is typically performed by a health care professional (e.g., physician, nurse, etc.), and wherein indirect administration includes a step of providing or making available the composition to the health care professional for direct administration (e.g., via injection, oral administration, dermal patch, etc.).
  • a health care professional e.g., physician, nurse, etc.
  • indirect administration includes a step of providing or making available the composition to the health care professional for direct administration (e.g., via injection, oral administration, dermal patch, etc.).
  • the numbers expressing quantities of ingredients, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term "about.” Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des compositions et des procédés d'amélioration énergétiques qui comprennent un stimulant végétal, de la théacrine et des composants de cannabis dans des rapports tels que le composant théacrine améliore un effet bénéfique du composant de stimulant végétal, et que le composant de cannabis réduit un effet négatif du composant de stimulant végétal. Les compositions envisagées peuvent en outre comprendre un ou plusieurs éléments parmi un composant de thé vert, un composant de gingembre, un composant de curcuma et un composant de vitamine pour améliorer encore l'effet bénéfique du composant de stimulant végétal.
PCT/US2017/067116 2016-12-16 2017-12-18 Compositions énergisantes et procédés WO2018112475A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435354P 2016-12-16 2016-12-16
US62/435,354 2016-12-16

Publications (1)

Publication Number Publication Date
WO2018112475A1 true WO2018112475A1 (fr) 2018-06-21

Family

ID=62559363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/067116 WO2018112475A1 (fr) 2016-12-16 2017-12-18 Compositions énergisantes et procédés

Country Status (1)

Country Link
WO (1) WO2018112475A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3711765A4 (fr) * 2017-12-29 2021-01-20 Hanyi Bio-Technology (Beijing) Co., Ltd. Composition contenant un extrait de cannabidiol/cannabis et de la caféine, et application de la composition
US11426410B2 (en) 2013-11-12 2022-08-30 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
WO2022197581A1 (fr) * 2021-03-17 2022-09-22 Tauriga Sciences Inc. Compositions médicamenteuses non orales à base de cannabinoïdes, procédés de fabrication et méthodes de traitement
US11583534B2 (en) 2013-11-12 2023-02-21 Ortho-Nutra, Llc Enhanced caffeinated beverage composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134300A1 (en) * 2004-12-20 2006-06-22 Newman Arnold L Nutritional supplement for caffeine-containing beverages
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
US8642097B1 (en) * 2013-03-19 2014-02-04 Nyangenya Maniga Natural product energy drink and method of use thereof
US20150132280A1 (en) * 2013-11-12 2015-05-14 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof
US20160324776A1 (en) * 2014-05-12 2016-11-10 HDDC Holdings, LLC Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134300A1 (en) * 2004-12-20 2006-06-22 Newman Arnold L Nutritional supplement for caffeine-containing beverages
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
US8642097B1 (en) * 2013-03-19 2014-02-04 Nyangenya Maniga Natural product energy drink and method of use thereof
US20150132280A1 (en) * 2013-11-12 2015-05-14 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof
US20160324776A1 (en) * 2014-05-12 2016-11-10 HDDC Holdings, LLC Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11426410B2 (en) 2013-11-12 2022-08-30 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
US11583534B2 (en) 2013-11-12 2023-02-21 Ortho-Nutra, Llc Enhanced caffeinated beverage composition
US11707465B2 (en) 2013-11-12 2023-07-25 Ortho-Nutra Llc Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
US11925645B2 (en) 2013-11-12 2024-03-12 Ortho-Nutra, Llc Enhanced caffeinated beverage composition
EP3711765A4 (fr) * 2017-12-29 2021-01-20 Hanyi Bio-Technology (Beijing) Co., Ltd. Composition contenant un extrait de cannabidiol/cannabis et de la caféine, et application de la composition
WO2022197581A1 (fr) * 2021-03-17 2022-09-22 Tauriga Sciences Inc. Compositions médicamenteuses non orales à base de cannabinoïdes, procédés de fabrication et méthodes de traitement

Similar Documents

Publication Publication Date Title
AU2021266209B2 (en) Theacrine-based supplement and method of use thereof
Zovko Koncic et al. New insights into dietary supplements used in sport: active substances, pharmacological and side effects
US20210220422A1 (en) Dietary supplement compositions and methods
US20090155392A1 (en) Methods and Systems for Sublingual Guarana Administration
US20040234544A1 (en) Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals
WO1999051252A1 (fr) Procede et composition servant a ameliorer la circulation sanguine
EP1744774A2 (fr) Composition nutritionnelle permettant de perdre du poids, de bruler des calories, d'augmenter la thermogenese, de favoriser le metabolisme energetique et/ou de suprrimer l'appetit
WO2018112475A1 (fr) Compositions énergisantes et procédés
AU2002364213A1 (en) Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
US20160303177A1 (en) Nutritional supplement
US7674484B2 (en) Dietary supplement including He Shou Wu, parasitic loranthus and green tea to promote weight loss
US20200100534A1 (en) Method of reducing weight regain in mammals
US11925645B2 (en) Enhanced caffeinated beverage composition
US20160303176A1 (en) Nutritional supplement
US20110189319A1 (en) Lifeforce liquid supplement
US11426439B2 (en) Nutritional product and method of using it
US20150157672A1 (en) Kits and methods for sustained weight loss
US20050069593A1 (en) Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid
US20220233621A1 (en) Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue
Yavuz et al. Herbs potentially enhancing sports performance.
CA2446254C (fr) Nouvelles compositions synergetiques de vitamines, de mineraux et d'oligoelements pour stimuler l'elimination des depots de lipide intracellulaire
RU2722728C1 (ru) Набор для контроля аппетита и нормализации веса тела и способ его применения
Končić Role of selected medicinal plants in sports nutrition and energy homeostasis
CN111093670A (zh) 基于特咖宁的补充剂及其与咖啡因协同组合中的使用方法
KR100835555B1 (ko) 기능성 초콜릿 조성물 그의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17881459

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17881459

Country of ref document: EP

Kind code of ref document: A1